Dr. Morris is the Chief Scientific Officer, responsible for overseeing the drug development processes for Solid Biosciences.
Prior to joining Solid, Dr. Morris was a Senior Director for Pfizer’s Rare Disease Research Unit, leading their efforts in neurologic diseases and the muscle biology programs. While at Pfizer, Dr. Morris directed several small molecule and biotherapeutic development programs, including a program that led to a Phase 2 study in Duchenne Muscular Dystrophy, while also heading an internal research group responsible for advancing programs from target identification to the clinic for many of the rare neurologic and muscle-related diseases. Dr. Morris identified key external opportunities and worked closely with patient groups, academic laboratories, and other industry partners to advance drug development in the rare neuromuscular space. His scientific and drug development experience at Pfizer also included investigations into broader muscle wasting conditions, as well as tendon and bone repair biology.
Prior to joining Pfizer in 2007, Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit, established to investigate strategies for improving muscle function during aging or disease. He completed his Postdoctoral fellowship in the Department of Physiology at the University of Pennsylvania where he worked on multiple projects ranging from molecular aspects of muscle protein interactions through to therapeutic approaches for modulating muscle size and function. As a trained muscle physiologist, his academic pursuits have ranged from biophysical aspects of muscle contraction and enzyme kinetics to therapeutic interventions in a variety of in vivo muscle atrophy and disease models.
Dr. Morris holds a B.A. in Biology from Franklin Pierce College (Rindge, NH) and a PhD in Physiology from UCLA.
What is Carl Ashley Morris' net worth?
The estimated net worth of Carl Ashley Morris is at least $189,893.60 as of January 27th, 2023. Dr. Morris owns 19,760 shares of Solid Biosciences stock worth more than $189,894 as of April 23rd. This net worth evaluation does not reflect any other investments that Dr. Morris may own. Learn More about Carl Ashley Morris' net worth.
How do I contact Carl Ashley Morris?
Has Carl Ashley Morris been buying or selling shares of Solid Biosciences?
Carl Ashley Morris has not been actively trading shares of Solid Biosciences during the last quarter. Most recently, Carl Ashley Morris sold 441 shares of the business's stock in a transaction on Friday, January 27th. The shares were sold at an average price of $7.49, for a transaction totalling $3,303.09. Following the completion of the sale, the insider now directly owns 19,760 shares of the company's stock, valued at $148,002.40. Learn More on Carl Ashley Morris' trading history.
Are insiders buying or selling shares of Solid Biosciences?
During the last twelve months, Solid Biosciences insiders bought shares 1 times. They purchased a total of 3,410,713 shares worth more than $18,861,242.89. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 30,674 shares worth more than $111,064.29. The most recent insider tranaction occured on January, 29th when Director Ilan Ganot sold 139 shares worth more than $1,110.61. Insiders at Solid Biosciences own 19.3% of the company.
Learn More about insider trades at Solid Biosciences. Information on this page was last updated on 1/29/2024.
